Terumo Corp. (OTCMKTS:TRUMY) Stock Short Interest Rises 150.5%

Terumo Corp. (OTCMKTS:TRUMY) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 54,335 shares, a growth of 150.5% from the October 15th total of 21,689 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 428,051 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

TRUMY has been the subject of several recent research reports. Zacks Research upgraded Terumo from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Nomura raised Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Two analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat.com, the company currently has an average rating of “Strong Buy”.

Terumo Stock Up 2.3%

OTCMKTS:TRUMY traded up $0.34 on Friday, reaching $15.02. The stock had a trading volume of 15,838 shares, compared to its average volume of 232,874. The company has a 50-day moving average of $14.81 and a 200 day moving average of $14.08. The company has a current ratio of 2.19, a quick ratio of 1.37 and a debt-to-equity ratio of 0.13. The stock has a market cap of $22.15 billion, a P/E ratio of 21.15 and a beta of 0.82. Terumo has a 12-month low of $12.08 and a 12-month high of $16.81.

Terumo (OTCMKTS:TRUMY) last announced its earnings results on Thursday, November 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). Terumo had a return on equity of 10.44% and a net margin of 13.83%. The business had revenue of $1.96 billion for the quarter, compared to analysts’ expectations of $1.94 billion. On average, research analysts predict that Terumo will post 0.86 earnings per share for the current year.

Terumo Company Profile

Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services. Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.